Emerging Pharmaceutical Strategies against Infectious Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 10 May 2024 | Viewed by 1359

Special Issue Editors


E-Mail Website1 Website2
Guest Editor
Departament of Pharmacy, School of Health Science, Universidad CEU Cardenal Herrera, C/Ramón y Cajal s/n, 46115 Alfara del Patriarca, Valencia, Spain
Interests: neglected diseases; infectious diseases; new drugs against infectious diseases
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, Madrid, Spain
Interests: nanomedicines; microparticles; sustained-release formulations; liposomes; nanoparticles; drug targeting; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Infectious diseases persist as a global health challenge, constantly presenting new hurdles for effective treatment. This Special Issue seeks to showcase pioneering research on drug delivery systems, targeted therapies, and novel formulations combating diverse infectious agents.

We welcome contributions that underscore the integration of cutting-edge technologies such as nanomedicine, immunotherapy, and personalized drug design to tackle the evolving complexities of infectious diseases. Researchers are encouraged to offer insights into the challenges and prospects of developing effective antiviral, antibacterial, and antifungal agents. Join us in shaping the trajectory of pharmaceutical interventions in the battle against infectious diseases. Submit your contributions to this Special Issue and play a pivotal role in advancing this critical field.

We look forward to receiving your contributions. 

Dr. M. Auxiliadora Dea-Ayuela
Dr. Dolores Remedios Serrano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibiotic activity
  • antibacterial activity
  • antifungal activity
  • antiviral activity
  • antimicrobial drug development
  • vaccine innovation
  • host-targeted therapies
  • precision medicine in infectious diseases
  • nanotechnology in antimicrobial therapeutics
  • drug delivery for infections

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3576 KiB  
Article
Influenza Virus Inactivated by Heavy Ion Beam Irradiation Stimulates Antigen-Specific Immune Responses
by Kai Schulze, Ulrich Weber, Christoph Schuy, Marco Durante and Carlos Alberto Guzmán
Pharmaceutics 2024, 16(4), 465; https://doi.org/10.3390/pharmaceutics16040465 - 27 Mar 2024
Viewed by 1171
Abstract
The COVID-19 pandemic has made clear the need for effective and rapid vaccine development methods. Conventional inactivated virus vaccines, together with new technologies like vector and mRNA vaccines, were the first to be rolled out. However, the traditional methods used for virus inactivation [...] Read more.
The COVID-19 pandemic has made clear the need for effective and rapid vaccine development methods. Conventional inactivated virus vaccines, together with new technologies like vector and mRNA vaccines, were the first to be rolled out. However, the traditional methods used for virus inactivation can affect surface-exposed antigen, thereby reducing vaccine efficacy. Gamma rays have been used in the past to inactivate viruses. We recently proposed that high-energy heavy ions may be more suitable as an inactivation method because they increase the damage ratio between the viral nucleic acid and surface proteins. Here, we demonstrate that irradiation of the influenza virus using heavy ion beams constitutes a suitable method to develop effective vaccines, since immunization of mice by the intranasal route with the inactivated virus resulted in the stimulation of strong antigen-specific humoral and cellular immune responses. Full article
(This article belongs to the Special Issue Emerging Pharmaceutical Strategies against Infectious Diseases)
Show Figures

Figure 1

Back to TopTop